# A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma

Source: https://onco.cc/trials/nct05987358/  
OnCo record `nct05987358` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing TQB3454 in biliary tract cancer, active and no longer recruiting.

## Summary

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma is a phase 3 interventional study registered as NCT05987358, led by Chia Tai Tianqing Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of TQB3454 Tablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation. Planned enrolment is 165 participants (estimated). The study started in 2023-09-21 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05987358
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of TQB3454 Tablets in the Treatment of Advanced Biliary Tract Cancer With Isocitrate Dehydrogenase 1 (IDH1) Mutation
- Sponsor: Chia Tai Tianqing Pharmaceutical
- Enrolled: 165

## Sources

- ClinicalTrials.gov NCT05987358: https://clinicaltrials.gov/study/NCT05987358

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- drugs: [TQB3454](https://onco.cc/drugs/tqb3454/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct05987358.json